{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:38:31Z","timestamp":1790775511775,"version":"4.1.0"},"reference-count":81,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The selection of an appropriate dose of a given antibiotic for a neonate not only requires knowledge of the drug\u2019s basic pharmacokinetic (PK) and pharmacodynamic (PD) properties but also the profound effects that organ development might have on the volume of distribution and clearance, both of which may affect the PK\/PD of a drug. Interest has grown in alternative antibiotic dosing strategies that are better aligned with the antibiotic\u2019s PK and PD properties. These strategies should be used in conjunction with minimum inhibitory concentration measurements and therapeutic drug monitoring to measure their potential success. They can also guide the clinician in tailoring the delivery of antibiotics to suit an individual patient\u2019s needs. Model-informed precision dosing, such as Bayesian forecasting dosing software (which incorporates PK\/PD population models), may be utilized to optimize antibiotic exposure in neonatal populations. Consequently, optimizing the antibiotic dose and exposure in each newborn requires expertise in different fields. It drives the collaboration of physicians together with lab technicians and quantitative clinical pharmacologists.<\/jats:p>","DOI":"10.3390\/antibiotics12121747","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T03:59:24Z","timestamp":1702871964000},"page":"1747","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetic and Pharmacodynamic Considerations of Antibiotic Use in Neonates"],"prefix":"10.3390","volume":"12","author":[{"given":"Mario","family":"Regazzi","sequence":"first","affiliation":[{"name":"S.I.F.E.B, Italian Society of Pharmacokinetics and Biopharmaceutics, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-7499","authenticated-orcid":false,"given":"Alberto","family":"Berardi","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Picone","sequence":"additional","affiliation":[{"name":"Neonatology and Neonatal Intensive Care Unit, Policlinico Casilino, 00169 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chryssoula","family":"Tzialla","sequence":"additional","affiliation":[{"name":"Neonatal and Pediatric Unit, Ospedale Civile Voghera, ASST Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Van den Anker, J.N., McCune, S., Annaert, P., Baer, G.R., Mulugeta, Y., Abdelrahman, R., Wu, K., Krudys, K.M., Fisher, J., and Slikker, W. (2020). Approaches to dose finding in neonates, Illustrating the variability between neonatal drug development programs. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070685"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2352-4642(21)00311-4","article-title":"Global, regional, and national causes of under-5 mortality in 2000\u201319: An updated systematic analysis with implications for the Sustainable Development Goals","volume":"6","author":"Perin","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cai, S., Thompson, D.K., Anderson, P.J., and Yang, J.Y. (2019). Short- and long-term neurodevelopmental outcomes of very preterm infants with neonatal sepsis: A systematic review and meta-analysis. Children, 6.","DOI":"10.3390\/children6120131"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpeds.2020.02.038","article-title":"Impact of Early-Onset Sepsis and Antibiotic Use on Death or Survival with Neurodevelopmental Impairment at 2 Years of Age among Extremely Preterm Infants","volume":"221","author":"Mukhopadhyay","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41372-021-01290-5","article-title":"The association between early-onset sepsis and neonatal encephalopathy","volume":"42","author":"Car","year":"2022","journal-title":"J. Perinatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bhat, V., and Bhandar, V. (2022). Does neonatal sepsis independently increase neurodevelopmental impairment?. Children, 9.","DOI":"10.3390\/children9040568"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/archdischild-2020-320217","article-title":"Global incidence and mortality of neonatal sepsis: A systematic review and meta-analysis","volume":"106","author":"Fleischmann","year":"2021","journal-title":"Arch. Dis. Child."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e200593","DOI":"10.1001\/jamapediatrics.2020.0593","article-title":"Early-onset neonatal sepsis 2015 to 2017, the rise of Escherichia coli, and the need for novel prevention strategies","volume":"174","author":"Stoll","year":"2020","journal-title":"JAMA Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clp.2021.05.003","article-title":"The term newborn: Early-onset sepsis","volume":"48","author":"Puopolo","year":"2021","journal-title":"Clin. Perinatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2022058813","DOI":"10.1542\/peds.2022-058813","article-title":"Late-onset sepsis among very preterm infants","volume":"150","author":"Flannery","year":"2022","journal-title":"Pediatrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2021052456","DOI":"10.1542\/peds.2021-052456","article-title":"Early-onset sepsis among very preterm infants","volume":"148","author":"Flannery","year":"2021","journal-title":"Pediatrics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.clp.2019.02.012","article-title":"Drugs for the prevention and treatment of sepsis in the newborn","volume":"46","author":"Mukhopadhyay","year":"2019","journal-title":"Clin. Perinatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Huncikova, Z., Stensvold, H.J., \u00d8ymar, K.A.A., Vatne, A., Lang, A.M., St\u00f8en, R., Brigtsen, A.K., Moster, D., Eriksen, B.H., and Selberg, T. (2023). Variation in antibiotic consumption in very preterm infants\u2014A 10 year population-based study. J. Antimicrob. Chemother., dkad358.","DOI":"10.1093\/jac\/dkad358"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0140-6736(17)31002-4","article-title":"Neonatal sepsis","volume":"390","author":"Shane","year":"2017","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rallis, D., Giapros, V., Serbis, A., Kosmeri, C., and Baltogianni, M. (2023). Fighting antimicrobial resistance in neonatal intensive care units: Rational use of antibiotics in neonatal sepsis. Antibiotics, 12.","DOI":"10.3390\/antibiotics12030508"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Garrido, F., Allegaert, K., Arribas, C., Villamor, E., Raffaeli, G., Paniagua, M., Cavallaro, G., and on behalf of European Antibiotics Study Group Easg (2021). Variations in antibiotic use and sepsis management in neonatal intensive care units: A European survey. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091046"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100727","DOI":"10.1016\/j.eclinm.2021.100727","article-title":"A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study","volume":"32","author":"Prusakov","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.1315","article-title":"Suggestions for model informed precision dosing to optimize neonatal drug therapy","volume":"59","author":"Euteneuer","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_19","unstructured":"European Commission (2023, October 30). Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Pediatric Use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/ECand Regulation (EC) No 726\/2004. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32006R1901."},{"key":"ref_20","unstructured":"(2023, October 30). Preparedness of Medicines\u2019 Clinical Trials in Paediatrics Recommendations by the Enpr-EMA Working Group on Trial Preparedness. 31 August 2020 EMA\/56009\/2019. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/preparedness-medicines-clinical-trials-paediatrics-recommendations-enpr-ema-working-group-trial_en.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Liu, Q., Liu, L., Yuan, Y., and Xie, F. (2023). A validated UHPLC\u2013MS\/MS method to quantify eight antibiotics in quantitative dried blood spots in support of pharmacokinetic studies in neonates. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020199"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2012.03.035","article-title":"Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and pharmacology","volume":"452","author":"Smits","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bcp.12752","article-title":"Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds","volume":"81","author":"Somani","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/QCO.0b013e328337bb42","article-title":"Understanding pharmacokinetics\/pharmacodynamics in managing neonatal sepsis","volume":"23","author":"Lutsar","year":"2010","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Butranova, O.I., Ushkalova, E.A., Zyryanov, S.K., and Chenkurov, M.S. (2023). Developmental pharmacokinetics of antibiotics Used in neonatal ICU: Focus on preterm infants. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030940"},{"key":"ref_26","first-page":"325","article-title":"Key Components for Antibiotic Dose Optimization of Sepsis in Neonates and Infants","volume":"29","author":"Pfister","year":"2018","journal-title":"Front. Pediatr."},{"key":"ref_27","unstructured":"Bennet, L.Z., Massoud, N., and Gambertoglio, J.G. (1983). Pharmacokinetic Basis for Drug Treatment, Raven Press."},{"key":"ref_28","unstructured":"Burton, M., Shaw, L.M., Shentag, J.J., and Evan, W.E. (2006). Applied Pharmacokinetics & Pharmacodymanics: Principles of Therapeutic Drug Monitoring, Lippincott Williams & Wilkins. [4th ed.]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00228-008-0599-y","article-title":"Clinical pharmacokinetics of aminoglycosides in the neonate: A review","volume":"65","author":"Pacifici","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"De Sutter, P.J., Rossignol, P., Bre\u00ebns, L., Gasthuys, E., and Vermeulen, A. (2023). Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15092348"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/pr.2014.143","article-title":"Dosing in neonates: Special considerations in physiology and trial design","volume":"77","author":"Ku","year":"2015","journal-title":"Pediatr. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2016.07.169","article-title":"Pharmacokinetics and Dosing of Anti-Infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature","volume":"38","author":"Sherwin","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.me.27.020176.001443","article-title":"Significance of serum protein and tissue binding of antimicrobial agents","volume":"27","author":"Craig","year":"1976","journal-title":"Annu. Rev. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jac\/11.3.233","article-title":"Effect of protein binding on antibiotic activity in vivo","volume":"11","author":"Merrikin","year":"1983","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1208\/ps040104","article-title":"Protein binding predictions in infants","volume":"4","author":"McNamara","year":"2002","journal-title":"AAPS PharmSci"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40272-015-0161-1","article-title":"Optimizing the Use of Antibacterial Agents in the Neonatal Period","volume":"18","author":"Cantey","year":"2016","journal-title":"Pediatr. Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3389\/fphar.2020.00587","article-title":"A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates","volume":"11","author":"Smits","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","article-title":"Cytochrome P450 3A: Ontogeny and drug disposition","volume":"37","author":"Kearns","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-013-0041-1","article-title":"Developmental changes in the expression and function of cytochrome P450 3A isoforms: Evidence from in vitro and in vivo investigations","volume":"52","author":"Ince","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/FTD.0b013e3181a8cc0a","article-title":"In vivo glucuronidation activity of drugs in neonates: Extensive interindividual variability despite their young age","volume":"31","author":"Allegaert","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/dmd.115.067900","article-title":"Interindividual variability in cytochrome P450\u2013mediated drug metabolism","volume":"44","author":"Tracy","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40262-015-0298-7","article-title":"Effect of kidney function on drug kinetics and dosing in neonates, infants, and children","volume":"54","author":"Rodieux","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/FTD.0b013e31806db3f5","article-title":"Renal drug clearance in preterm neonates: Relation to prenatal growth","volume":"29","author":"Allegaert","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: Which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Gasc\u00f3n, A., Solin\u00eds, M.\u00c1., and Isla, A. (2021). The role of PK\/PD analysis in the development and evaluation of antimicrobials. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060833"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Men, P., Li, H.-B., Zhai, S.-D., and Zhao, R.-S. (2016). Association between the AUC0-24\/MIC ratio of vancomycin and its clinical effectiveness: A systematic review and meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146224"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.coph.2011.07.006","article-title":"Revisiting beta-lactams-PK\/PD improves dosing of old antibiotics","volume":"11","author":"MacGowan","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-012-0015-8","article-title":"Population pharmacokinetic analysis during the first 2 years of life: An overview","volume":"51","author":"Marsot","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s002280100355","article-title":"Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation","volume":"57","author":"Bleyzac","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/01.ftd.0000198648.39751.11","article-title":"Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates","volume":"28","author":"Pullen","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1128\/AAC.49.7.2760-2766.2005","article-title":"Population pharmacokinetics of cefepime in the neonate","volume":"49","author":"Capparelli","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2710.2008.00913.x","article-title":"Population pharmacokinetics of cefepime in neonates with severe nosocomial infections","volume":"33","author":"Noyola","year":"2008","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000457554","article-title":"3rd. Population pharmacokinetics of ceftizoxime in premature newborns","volume":"20","author":"Karna","year":"1993","journal-title":"Dev. Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/j.1875-9114.1992.tb04506.x","article-title":"Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixedeffects model","volume":"12","author":"Jensen","year":"1992","journal-title":"Pharmacotherapy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00228-003-0663-6","article-title":"Population pharmacokinetics of gentamicin in South African newborns","volume":"59","author":"Botha","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/jac\/dkl244","article-title":"Population pharmacokinetics of gentamicin in premature newborns","volume":"58","author":"Barcia","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200948040-00003","article-title":"Developmental pharmacokinetics of gentamicin in preterm and term neonates: Population modelling of a prospective study","volume":"48","author":"Nielsen","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/INF.0b013e318170f8d2","article-title":"Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate","volume":"27","author":"Bradley","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00007691-199812000-00005","article-title":"Population pharmacokinetics of vancomycin in Japanese pediatric patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","article-title":"Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance","volume":"63","author":"Anderson","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/978-981-10-4166-2_114","article-title":"The role of population pharmacokinetic analysis in rational antibiotic therapy in neonates","volume":"Volume 62","author":"Badnjevic","year":"2017","journal-title":"CMBEBIH 2017. IFMBE Proceedings"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1128\/AAC.02214-15","article-title":"Clinical utility and safety of a model-based patient-tailored dose of vancomycin in neonates","volume":"60","author":"Leroux","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Blanco, J.S., and Lanao, J.M. (2022). Model-Informed Precision Dosing (MIPD). Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122731"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00007691-200202000-00002","article-title":"Potential Benefit of Bayesian Forecasting for Therapeutic Drug Monitoring in Neonates","volume":"24","author":"Pons","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin. Pharm. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"624639","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: A narrative review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/17425255.2016.1147559","article-title":"Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period","volume":"12","author":"Samardzic","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sinkeler, F.S., de Haan, T.R., Hodiamont, C.J., Bijleveld, Y.A., Pajkrt, D., and Math\u00f4t, R.A. (2014). Inadequate vancomycin therapy in term and preterm neonates: A retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. BMC Pediatr., 14.","DOI":"10.1186\/1471-2431-14-193"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13052-015-0117-7","article-title":"Antimicrobial therapy in neonatal intensive care unit","volume":"41","author":"Tzialla","year":"2015","journal-title":"Ital. J. Pediatr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"151322","DOI":"10.1016\/j.semperi.2020.151322","article-title":"Association of early life antibiotics and health outcomes: Evidence from clinical studies","volume":"44","author":"Ting","year":"2020","journal-title":"Semin. Perinatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41390-021-01842-7","article-title":"Invasive fungal infections in neonates: A review","volume":"91","author":"Weimer","year":"2022","journal-title":"Pediatr. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpeds.2018.07.036","article-title":"Early antibiotic exposure and adverse outcomes in preterm, very low birth weight infants","volume":"203","author":"Cantey","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e20182286","DOI":"10.1542\/peds.2018-2286","article-title":"Duration of initial empirical antibiotic therapy and outcomes in very low birth weight infants","volume":"143","author":"Ting","year":"2019","journal-title":"Pediatrics"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jpeds.2021.11.075","article-title":"Early antibiotic exposure and adverse outcomes in very preterm infants at low risk of early-onset sepsis: The EPIPAGE-2 Cohort Study","volume":"243","author":"Letouzey","year":"2022","journal-title":"J. Pediatr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jpeds.2022.09.029","article-title":"Early empirical antibiotics and adverse clinical outcomes in infants born very preterm: A population-based cohort","volume":"253","author":"Vatne","year":"2023","journal-title":"J. Pediatr."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Awujoola, A., Torga, A.P., Abdul Ghayum, M.A., Mousa, N., Olorunsogo, T., DeSilva, S., Avades, M., Prince, O., and Ankola, P. (2023). Neonatal ampicillin\/gentamicin exposure and the risk of childhood obesity in South Bronx pediatric population. Am. J. Perinatol.","DOI":"10.1055\/s-0043-1774315"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41467-023-38156-7","article-title":"Less is more: Antibiotics at the beginning of life","volume":"14","author":"Stocker","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S1473-3099(22)00726-5","article-title":"Multinational consensus antimicrobial stewardship recommendations for children managed in hospital settings","volume":"23","author":"McMullan","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"151324","DOI":"10.1016\/j.semperi.2020.151324","article-title":"Principles, policy and practice of antibiotic stewardship","volume":"44","author":"Akinboyo","year":"2020","journal-title":"Semin. Perinatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/jcpt.13553","article-title":"Impact of pharmacist intervention in antibiotic stewardship programmes for critically ill neonates: A systematic review and meta-analysis","volume":"47","author":"Lee","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Unni, J.C., Chacko, M., Jacob, J., and Warrier, A. (Am. J. Infect. Control, 2023). Randomised control trial on impact of clinical pharmacist led interventions on antibiotic stewardship program in children 0 to 18 years age in a tertiary care hospital in southern India, Am. J. Infect. Control, in press.","DOI":"10.1016\/j.ajic.2023.11.010"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/12\/1747\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:40:33Z","timestamp":1760132433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/12\/1747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":81,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["antibiotics12121747"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12121747","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}